| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total comprehensive (loss) income | -43,913 | -43,140 | -16,869 | -12,731 |
| Net (loss) income per share, basic (in dollars per share) | -1.06 | -1.04 | -0.42 | -0.35 |
| Net (loss) income per share, diluted (in dollars per share) | -1.06 | -1.04 | -0.42 | -0.35 |
| Weighted-average common shares outstanding, basic (in shares) | 41,462,567 | 41,338,752 | 41,073,732 | 40,629,602 |
| Weighted-average common shares outstanding, diluted (in shares) | 41,462,567 | 41,338,752 | 41,073,732 | 40,629,602 |
Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. (TRDA)